Equillium (NASDAQ: EQ) operates within the competitive biotechnology sector alongside several clinical-stage biopharmaceutical peers focused on severe immunological and autoimmune diseases. Its primary market competitors and comparable small-cap healthcare entities include Immix Biopharma, Autolus Therapeutics, Shattuck Labs, AgomAb Therapeutics, and REGENXBIO.